We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Evaluation of Neuroprotective Effect of Minocycline (minocyclin &RD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01297816
Recruitment Status : Unknown
Verified December 2010 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : February 17, 2011
Last Update Posted : February 17, 2011
Information provided by:

January 19, 2011
February 17, 2011
February 17, 2011
December 2010
December 2010   (Final data collection date for primary outcome measure)
BCVA [ Time Frame: changes of BCVA in 3 month ]
outcome method of measurement: Snellen chart
Same as current
No Changes Posted
  • finding of ERG changes [ Time Frame: 3 months ]
    outcome method of measurement: ERG( testes)
  • finding of OCT changes [ Time Frame: 3 months ]
    outcome method of measurement: OCT
  • finding of FAF changes [ Time Frame: 3 months ]
    outcome method of measurement: FAF( testes)
Same as current
Not Provided
Not Provided
Evaluation of Neuroprotective Effect of Minocycline
Evaluation of Minocycline Neuro Protective Role in Retinal Detachment Surgery

This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .

Process of degeneration begins from first hours of RD (Retinal Detachment) establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years .

How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researcher.

In the study the investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study

Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Retinal Detachment
  • Drug: placebo
    100mg,BD, fo three month
  • Drug: Minocycline
  • Placebo Comparator: placebo
    Intervention: Drug: placebo
  • Placebo Comparator: minocyclin
    Intervention: Drug: Minocycline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
Not Provided
April 2011
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • age over 8 years old
  • gender of both sex
  • normal liver and renal function
  • informed consent received from all patients
  • no pregnancy and no lactation
  • minimal sun exposure

Exclusion Criteria:

  • old RD
  • diabetic retina
  • previous retinal surgery CRF& liver disfunction RD + PVR > B Hyper sensitivity to tetracycline History previous MPC or PRP Patients unsuccessful SB (retina is off )
Sexes Eligible for Study: All
8 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
Not Provided
Not Provided
Mohsen Azarmina, Ophthalmic Research center
Shahid Beheshti University of Medical Sciences
Not Provided
Not Provided
Shahid Beheshti University of Medical Sciences
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP